Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trillium Therapeutics

Vir Biotechnology

Small-cap biotechs focused on virus treatments and cures have soared in recent weeks, but most folks should avoid these risky stocks.

Small-Cap Biotech Stocks Soar on Coronavirus Speculation

Apple

Inovio Pharmaceuticals

Moderna

Professional money managers are looking to buy stocks that act as a hedge against coronavirus threat, or those that simply benefits from the particular event.

4 Top Stocks to Win Big From the Coronavirus Pandemic

Novavax

Progress with new COVID-19 tests and experimental vaccines in early-stage development sent these stocks flying higher.

3 Coronavirus Stocks That Soared Last Week

Alpha Pro Tech

Clorox

Gilead Sciences

These seven stocks could protect your portfolio against the SARS-CoV-2 outbreak.

7 Stocks to Buy as a Hedge Against The Coronavirus Threat

Some of the top stocks in 2020 are the companies that are fighting the coronavirus.

3 Small-Caps That Are Soaring Because of Coronavirus Panic

I say this now, but the full scope of that realization only really hit me during Thursday’s session when, right on the opening bell, I fell into the red by more than $7,000 on just 3,000 shares of Co-Diagnostics, Inc.

From Blue Chips To Penny Stock, The Market's Physics Have Changed

While most stocks and markets have taken big hits, these three coronavirus stocks have been among the most explosive opportunities.
The post 3 Coronavirus Stocks to Own Until the Fear Fades appeared first on InvestorPlace.

3 Coronavirus Stocks to Own Until the Fear Fades

Stamps.com

Uniti Group

Vaxart

Wall Street has entered into the correction territory after steep coronavirus-induced selloffs in February. But these stocks have gained massively.

Market in Correction: 5 Stocks Resist Virus Attack in February

Hint: It's not Inovio, Moderna, or Novavax.

This Under-the-Radar Stock Is the Biggest Winner From the Coronavirus Outbreak

Shares of Co-Diagnostics Inc. CODX, +54.69% , a molecular diagnostics company that has developed a test for the coronavirus, rose another 57% on Thursday, bringing its month-to-date gains to 333%, after the company said it has received a CE Mark for its test.

Co-Diagnostics stock soars 57% on high hopes for its coronavirus test

Johnson & Johnson

Pulmatrix

January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.

The Wining Sector & Its Top Stocks in Virus-Infected January

Allied Healthcare Products

BioCryst Pharmaceuticals

Cerus

Dyadic International Inc., DE

Lakeland Industries

NanoViricides

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

12 Stocks Surging That Could Help Treat or Fight Coronavirus

Shares of a handful of vaccine makers, diagnostics companies and manufacturers of medical supplies, like masks, rallied again in premarket trading on Monday over growing public concern about the new coronavirus. This includes Co-Diagnostics Inc.

Vaccine, diagnostics stocks rise again on spreading coronavirus

American Airlines

Delta Air Lines

Estee Lauder

LVMH Moet Hennessy Louis Vuitton

Royal Caribbean Cruises

United Continental Hlds

So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.

Coronavirus Spooks Global Markets: Winners and Losers

Shares of Co-Diagnostics Inc. CODX, +79.65% tumbled 16% in premarket trading Friday, after the molecular diagnostics company took advantage of the prior session's big rally to enter into a stock sale agreement.

Co-Diagnostics' stock tumbles after stock sale agreement priced at 29% discount

Aethlon Medical

AstraZeneca

Cleveland BioLabs

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

Shares of molecular diagnostic company Co-Diagnostics Inc (NASDAQ: CODX) are riding high on the Wuhan coronavirus wave, at their highest level in about a year.

Co-Diagnostics Rallies On Plans To Develop Screening Test For Coronavirus

Shares of Co-Diagnostics Inc. CODX, -1.74% nearly tripled (up 177%) on heavy volume in premarket trading Thursday, after the molecular diagnostics company said it had completed principle design work for a polymerase chain reaction (PCR) screening test for new coronavirus.

Co-Diagnostics stock nearly triples after completion of design work for coronavirus screener

CoSara tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus recently granted regulatory approval by CDSCO to formally launch at India Diagnostic Expo CoSara tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus recently granted regulatory approval by CDSCO to formally launch at India Diagnostic Expo

Co-Diagnostics and CoSara to Launch IVD Products to India Market

Company completes sale and installation to one of the largest private molecular diagnostics labs in Ghana Company completes sale and installation to one of the largest private molecular diagnostics labs in Ghana

Co-Diagnostics, Inc. Continues to Execute on International Expansion

Vector Smart™ ZDC multiplex PCR test to aid prevention of tropical disease proliferation in the US and abroad Vector Smart™ ZDC multiplex PCR test to aid prevention of tropical disease proliferation in the US and abroad

Co-Diagnostics, Inc. Adds to Menu of Molecular Vector Control Products

Company will host booth to introduce and promote mosquito abatement products to midwestern states in Tulsa, OK on Sept 19-20 Company will host booth to introduce and promote mosquito abatement products to midwestern states in Tulsa, OK on Sept 19-20

Co-Diagnostics, Inc. to Launch Vector Control Products into Midwest US at OPMA Conference

Salt Lake City, Utah, Aug.  28, 2019  (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be featured as a presenting company at the 21st Annual Rodman and Renshaw Global Investment Conference on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City.

Co-Diagnostics, Inc. to Present at 21st Annual Rodman & Renshaw Global Investment Conference Sept 8-10, 2019

Event to include demos and training for distributors and end-users of Company’s products Event to include demos and training for distributors and end-users of Company’s products

Co-Diagnostics, Inc. to Host 2nd Semiannual Distributor Conference on Sept 10-12

Co-Diagnostics, Inc. (NASDAQ: CODX) shared positive results of a study to detect cancer mutations using its patented CoPrimer technology, with applications in liquid biopsy and companion diagnostic tests.

Thursday's Big Winner: Co-Diagnostics

News for Co-Diagnostics Stock (CODX)